Rumor Has It: Expect Valeant Divestitures?
The plagued specialty pharma has been rumored to have at least one suitor, but analysts are skeptical and expect multiple divestitures will be required if the company is going to gain back some of its losses.
You may also be interested in...
Takeda and Valeant are rumored to have restarted talks over some form of potential deal, this time reportedly focusing on a possible offer by the Japanese firm for Valeant's gastrointestinal business unit Salix.
The beleaguered spec pharma's new CEO set the tenor for the company going forward as he laid out plans for a turnaround during a first quarter call.